Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Assets (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Assets data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Assets fell 21.49% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 21.49%, while the annual FY2025 figure was $1.1 billion, 21.49% down from the prior year.
  • Assets reached $1.1 billion in Q4 2025 per CRNX's latest filing, down from $1.2 billion in the prior quarter.
  • Across five years, Assets topped out at $1.4 billion in Q4 2024 and bottomed at $163.5 million in Q1 2021.
  • Average Assets over 5 years is $678.8 million, with a median of $528.5 million recorded in 2022.
  • Peak YoY movement for Assets: tumbled 30.46% in 2023, then skyrocketed 219.02% in 2024.
  • A 5-year view of Assets shows it stood at $351.0 million in 2021, then grew by 0.33% to $352.2 million in 2022, then skyrocketed by 80.41% to $635.4 million in 2023, then skyrocketed by 125.79% to $1.4 billion in 2024, then fell by 21.49% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $1.1 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.3 billion in Q2 2025.